DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.502
-0.016 (-3.07%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.518
Open0.520
Bid0.000 x 1400
Ask0.000 x 4000
Day's Range0.500 - 0.525
52 Week Range0.420 - 3.080
Volume50,607
Avg. Volume372,540
Market Cap25.364M
Beta-1.81
PE Ratio (TTM)N/A
EPS (TTM)-1.936
Earnings DateMar 29, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Zacks Small Cap Research9 days ago

    DFFN: Preparing for Phase 2 Clinical Trial of TSC in Acute Stroke

    In early 2018, Diffusion (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • GlobeNewswire14 days ago

    Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trial Key U.S. Patent Issued Clinical trial preparations are ongoing for Phase 2 trial with TSC in stroke CHARLOTTESVILLE, ...

  • Zacks Small Cap Researchlast month

    DFFN: Enrollment in Phase 3 GBM Trial Continuing

    On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for 2017 and provided a business update. The primary outcome of the study is overall survival at two years between the two groups.

  • ACCESSWIRE2 months ago

    Diffusion Pharmaceuticals to Present at The MicroCap Conference

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy ...

  • GlobeNewswire2 months ago

    Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update

    Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual ...

  • Zacks Small Cap Research3 months ago

    DFFN: Phase 3 GBM Trial Underway; Planning for Phase 2 Trial in Stroke

    On January 29, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced that the first patient has been dosed in the Phase 3 clinical trial of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation and potentially improve outcomes associated with radiation and chemotherapy cancer treatments. The trial has been named INTACT (INvestigating Tsc Against Cancerous Tumors) and is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis.

  • Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price
    SmarterAnalyst4 months ago

    Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price

    Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as of this writing. Diffusion announced this morning that it will be selling at least 15 million shares of its own stock to raise cash for research and development of the company's lead product candidate, transcrocetinate sodium, including clinical trial activities, and for general corporate purposes. Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanying common warrant. The common warrants will be exercisable at an exercise price of $0.80 per share and will expire five years from the date of issuance.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Diffusion Pharmaceuticals and Pain Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Diffusion Pharmaceuticals and Pain Therapeutics were two biotech stocks scorching on Tuesday. Shares of Pain Therapeutics even hit a new high after announcing ...

  • Breaking Down Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN) Ownership Structure
    Simply Wall St.5 months ago

    Breaking Down Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN) Ownership Structure

    In this article, I’m going to take a look at Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Interested In Healthcare? Why Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) May Be The Entry Point
    Simply Wall St.5 months ago

    Interested In Healthcare? Why Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) May Be The Entry Point

    Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a USD$19.46M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • What You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) Risks
    Simply Wall St.6 months ago

    What You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) Risks

    If you are looking to invest in Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM
    Zacks Small Cap Research6 months ago

    DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM

    On November 13, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the third quarter of 2017. As expected, the company did not report any revenues. Diffusion reported net income of $5.1 million, or $0.37 per share, which was the result of a non-cash gain of $8.4 million related to the change in the fair value of warrant liabilities due to a decrease in the fair market value of the company’s common stock and not indicative of ongoing operations.

  • ACCESSWIRE7 months ago

    Today's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 18, 2017 / Shares of Neothetics and Diffusion Pharmaceuticals saw big gains in Tuesday trading after the companies had positive news respectively. Neothetics soared ...

  • Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%
    SmarterAnalyst7 months ago

    Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%

    Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 35% upturn. The US drug discovery and development firm announced that it has received final protocol guidance from the FDA for a Phase 3 clinical trial with the Company’s lead compound trans sodium crocetinate (TSC) in patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer. The Company has responded to all outstanding points raised by the FDA and plans to begin the trial under the protocol agreed to by the FDA by the end of 2017.

  • Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?
    Simply Wall St.8 months ago

    Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?

    Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Diffusion Pharmaceuticals Is DFFN still cheap? Great news forRead More...